Application of apigenin to prepare medicine for treating pancreatic cancer

Abstract

The invention belongs to the field of pharmacy, and relates to an application of a TCM monomer of apigenin to prepare a medicine for treating the pancreatic cancer. A CCK-8 method for evaluation, repeated screening and optimization, and a pharmacodynamic test for inhibiting proliferation of pancreatic cancer SW1990 cells are adopted to screen an effective monomer, having a strong anti-tumor effect, of apigenin. Moreover, an equipment of apigenin for interfering a Sonic Hedgehog signal channel of human pancreatic cancer SW1990 stem cells is carried out. The result shows that apigenin can obviously inhibit proliferation of pancreatic cancer stem cells, lower the ratio of pancreatic cancer stem cells, and reduce self-renewable ability of pancreatic cancer stem cells. The ratio of CD24+CD44+ cells is obviously lowered through flow cytometry; the amount of cancer stem cells cultured free of serum decreases; and expression of members in the Sonic Hedgehog signal channel at mRNA and protein levels is obviously lowered. The TCM monomer of apigenin can be taken as an individual unique active component for preparing the medicine for treating the pancreatic cancer.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to drugs for treating pancreatic cancer, in particular to the use of apigenin, a monomer of traditional Chinese medicine, in the preparation of drugs for treating pancreatic cancer. Background technique [0002] Existing technology Studies on tumors have shown that the existence of tumor stem cells has been confirmed, especially in blood tumors, brain tumors and breast cancer studies, and studies have discovered a cell subgroup that plays a major role in tumorigenesis and development , which is characterized by the specific expression of CD44, CD24 and ESA (epithelial-specific antigen, epithelial cell-specific antigen). Studies have shown that in pancreatic cancer cells, about 0.2–0.8% of the cells express CD44+CD24+ESA+, and Other pancreatic cancer cells are 100 times more carcinogenic than other pancreatic cancer cells. CD44+CD24+ESA+ pancreatic cancer cells can self-replicate, differentiate ...

AI Technical Summary

Problems solved by technology

In recent years, the industry has carried out some studies on the effective components or components of traditional Chinese medicines for the treatment of pancreatic cancer, and found some effective components or components of traditional Chinese medicines that have different degrees of inhibition of pancreatic cancer cells. Yihuaji recipe) or a single active ingredient, all have their shortcomings

Due to the complex composition of traditional Chinese medicine compound, it is difficult to understand its ingredients, which makes its preparations have certain controllability and stability problems. In view of the characteristic advantages of treating complex diseases; in view of this problem, the inventor of the present application intends to provide new drugs for the treatment of pancreatic cancer through the research on the inhibition of human pancreatic cancer stem cells and its mechanism, especially the preparation of traditional Chinese medicine monomer apigenin New use in pancreatic cancer drug

Images